Evaluating 18F-MFBG PET Imaging for Pheochromocytoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients diagnosed with pheochromocytoma. It focuses on the advantages of 18F-MFBG over traditional imaging methods, particularly its ability to provide better image quality and quicker imaging times. Patients with suspected or confirmed pheochromocytoma will be enrolled, and the study will evaluate the safety profile and effectiveness of this imaging technique. The goal is to improve diagnostic accuracy and facilitate better clinical management of the condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged 30-80 years old, primary school or above, with a regular caregiver;
2. Clinically diagnosed patients with pheochromocytoma;
3. Can provide informed consent, can understand and comply with the study requirements.

Exclusion Criteria:

1. Patients with serious primary diseases such as heart, brain, liver, kidney and hematopoietic system;
2. Uncontrolled hypertension or high-risk BP (i.e., systolic BP \> 180 mmHg or diastolic BP \> 110 mmHg);
3. Patients with mental disorders or primary affective disorders;
4. Unable to understand and adhere to the study protocol or provide informed consent;
5. Contraindications to PET imaging (including pregnant women, lactating women, and women of childbearing age with recent childbearing plans, etc.);
6. Allergy to imaging agents;
7. Patients who were unable to cooperate with PET scanning, such as hypoglycemia, severe pain or tremor.

Where it's running

• The First Affiliated Hospital of Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting
• The First Affiliated Hospital Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Peipei Wang, MD
• Email: wpp199411@163.com
• Phone: 86 18511395988

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Belzutifan and catecholamine metabolism in pheochromocytoma/paraganglioma

  This study tests whether Belzutifan can change how catecholamines are produced and broken down in adults with pheochromocytoma or paraganglioma.

  Recruiting Phase 2 Cambridge University Hospitals NHS Foundation Trust · Cambridge, Cambridgeshire · NCT07680205

• Cardiovascular Outcomes After Adrenalectomy for Pheochromocytoma and Non-secreting Tumors

  This study tests how often and what kinds of cardiovascular problems occur after adrenalectomy for pheochromocytoma or non-secreting tumors.

  Recruiting Central Hospital, Nancy, France · Vandœuvre-lès-Nancy, Lorraine · NCT07200245

• NET- and somatostatin-targeted PET/SPECT imaging to find and stage neuroblastoma and pheochromocytoma/paraganglioma

  This study will try different PET and SPECT tracers to see if they can accurately find and stage tumors in children and adults with neuroblastoma or pheochromocytoma/paraganglioma.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07195500

• Combining Lutathera® and Olaparib for treating recurrent solid tumors in children and adolescents

  This study is testing if combining Lutathera® with olaparib can help children and teenagers with hard-to-treat solid tumors that have certain receptors.

  Recruiting Phase 1/2 Fundación de investigación HM · Boadilla del Monte, Madrid · NCT06607692

• Registry for Rare Diseases

  This study is creating a detailed registry to collect information on rare diseases like amyloidosis and sarcoidosis to help improve how they are diagnosed and treated.

  Recruiting Hospital Italiano de Buenos Aires · Buenos Aires, Buenos Aires · NCT06573723

• Understanding genetic causes of neuroendocrine tumors in Mexican patients

  This study is trying to find out the genetic changes that cause neuroendocrine tumors in Mexican patients to help develop better treatments.

  Recruiting at 3 sites Universidad Nacional Autonoma de Mexico · Mexico City, Mexico City and 2 other locations · NCT06523582

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.